{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 43,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "The table uses a color-coded heatmap to highlight favorable (green) vs unfavorable (pink) characteristics of clinical trial data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/15",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.75,
        "x": 0.215,
        "y": 0.905
      },
      "kind": "disclaimer",
      "text": "WKA Yung, et al, British Journal Cancer, Aug 8, 2000; Teri Kreisl, et all, Journal Clinical Onocoloy,2009, Feb 10;27(5);740-5; Tracy Batchelor, et. all, Journal of Clinical Oncology, vol28, issue 17, Jun 10, 2010; David Reardon, et al, Clin Cancer Research Apr 2020; 26(7)1586-1594; Martin van den Bent, et al, Cancer Chemo & Pharma, 26 Oct 2017 80, 1209-1217; Yazmin Odia, et al, Journal Neuro-Oncology 127, 127-125 (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12c1cf79-a154-449a-9fd8-e16ef7e2be1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.19,
        "x": 0.08,
        "y": 0.875
      },
      "kind": "legend",
      "text": "Positive Neutral Negative Characteristics",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dad4583-2c0f-4f3c-9e93-e27cc99acb7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.94,
        "x": 0.03,
        "y": 0.145
      },
      "kind": "table",
      "text": "Comparative analysis table of GBM agents",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bd30acd-f8c1-4ce2-b428-ff60e2bac173",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.784,
        "x": 0.108,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strong rationale for phase 3 success relative to recent GBM trials",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dc23c4f-fda5-4e2a-854e-d9cd31b1941b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "9071d53a-b9a2-4cf7-bfe9-0355020b1cd7",
      "evidence": "Structured comparison of clinical trial outcomes across multiple agents",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "ccc4bb10-21c5-4108-a909-a6dcfbb735cf",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck presents efficacy data and analysis to agitate the need for better treatment options",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94af67d1-e80e-42ee-8d7b-9970ecae23e8",
      "evidence": "The deck presents data on the high unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "What is the cost of not treating H3 K27M-mutant diffuse glioma effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}